Scheduled Maintenance Notice
Please note that Researcher Profiles will be undergoing scheduled maintenance on Wednesday 7th Oct, from 8:00am to 9:00am. During this time, the Researcher Profiles system will be unavailable. We apologise for any inconvenience and appreciate your understanding.
Select Publications
Conference Abstracts
, 2025, 'Abstract B079: The glycogen synthase kinase-3β inhibitor 9-ING-41 in combination with chemoimmunotherapy provides long-term survival in the Th-MYCN mouse model', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), Vol. 24, pp. b079 - b079, http://dx.doi.org/10.1158/1535-7163.targ-25-b079
, 2024, 'Abstract C018: Spatial profiling of tumor associated cells expressing endoplasmic reticulum stress proteins predicts poor outcomes in pancreatic cancer patients', in Cancer Research, American Association for Cancer Research (AACR), Vol. 84, pp. c018 - c018, http://dx.doi.org/10.1158/1538-7445.panca2023-c018
, 2024, '24 (PB012): Runx1t1 is an epigenetic regulator essential for MYCN-driven neuroblastoma tumorigenesis', in European Journal of Cancer, Elsevier, Vol. 211, pp. 114552, http://dx.doi.org/10.1016/j.ejca.2024.114552
, 2021, 'Targeting chromatin potently inhibits leukemia progression in MLL-rearranged leukemia models', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 15 - 15
, 2021, 'HGG-09. TARGETING FACILITATES CHROMATIN TRANSCRIPTION (FACT) AS A NOVEL STRATEGY THAT ENHANCES RESPONSE TO HISTONE DEACETYLASE (HDAC) INHIBITION IN DIPG', in Neuro-Oncology, Oxford University Press (OUP), Vol. 23, pp. i18 - i19, http://dx.doi.org/10.1093/neuonc/noab090.075
, 2021, 'RARE-02. POLYAMINE PATHWAY INHIBITION IS A POTENT NOVEL THERAPEUTIC STRATEGY AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', in Neuro-Oncology, Oxford University Press (OUP), Vol. 23, pp. i40 - i41, http://dx.doi.org/10.1093/neuonc/noab090.163
, 2020, 'DIPG-15. POLYAMINE PATHWAY INHIBITION IS A POTENT NOVEL THERAPEUTIC STRATEGY AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', in Neuro-Oncology, Oxford University Press (OUP), Vol. 22, pp. iii289 - iii290, http://dx.doi.org/10.1093/neuonc/noaa222.065
, 2020, 'DIPG-16. COMBINATION OF ARGININE DEPLETION AND POLYAMINE INHIBITION AS AN ANTICANCER STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)', in Neuro-Oncology, Oxford University Press (OUP), Vol. 22, pp. iii290 - iii290, http://dx.doi.org/10.1093/neuonc/noaa222.066
, 2020, 'DIPG-27. TARGETING FACILITATES CHROMATIN TRANSCRIPTION (FACT) AS A NOVEL STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) THAT ENHANCES RESPONSE TO HISTONE DEACETYLASE (HDAC) INHIBITION', in Neuro-Oncology, Oxford University Press (OUP), Vol. 22, pp. iii292 - iii292, http://dx.doi.org/10.1093/neuonc/noaa222.076
, 2020, 'DIPG-75. PRECISION MEDICINE FOR PAEDIATRIC HIGH-GRADE DIFFUSE MIDLINE GLIOMAS - RESULTS FROM THE ZERO CHILDHOOD CANCER COMPREHENSIVE PRECISION MEDICINE PROGRAM', in Neuro-Oncology, Oxford University Press (OUP), Vol. 22, pp. iii302 - iii302, http://dx.doi.org/10.1093/neuonc/noaa222.117
, 2020, 'COMBINATION OF ARGININE DEPLETION AND POLYAMINE INHIBITION AS AN ANTICANCER STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 22, pp. 290 - 290, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000606080100067&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'Abstract SY09-02: Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer in Australia', in Cancer Research, American Association for Cancer Research (AACR), Vol. 80, pp. sy09-02-sy09-02, http://dx.doi.org/10.1158/1538-7445.am2020-sy09-02
, 2020, 'Abstract A35: P-Glycoprotein is a resistance mechanism for conventional induction chemotherapy but not ALK inhibitors in high-risk neuroblastoma', in Cancer Research, American Association for Cancer Research (AACR), Vol. 80, pp. a35 - a35, http://dx.doi.org/10.1158/1538-7445.pedca19-a35
, 2020, 'Abstract A52: Zero Childhood Cancer (ZERO): A comprehensive precision medicine platform for children with high-risk cancer', in Cancer Research, American Association for Cancer Research (AACR), Vol. 80, pp. a52 - a52, http://dx.doi.org/10.1158/1538-7445.pedca19-a52
, 2019, 'Zero Childhood Cancer: A Comprehensive Precision Medicine Platform for Children and Adolescents with High-Risk Cancer', in PEDIATRIC BLOOD & CANCER, WILEY, Vol. 66, pp. S504 - S505, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488458005162&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2019, 'Molecular targeted therapies and precision medicine for children with neuroblastoma and other refractory malignancies', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CANADA, Montreal, Vol. 80, pp. 23 - 24, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, CANADA, Montreal, 17 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2019, 'P-Glycoprotein is a resistance mechanism for conventional induction chemotherapy but not ALK inhibitors in high-risk neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CANADA, Montreal, Vol. 80, pp. 61 - 61, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, CANADA, Montreal, 17 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400079&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2019, 'Zero Childhood Cancer (ZERO): A comprehensive precision medicine platform for children with highrisk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CANADA, Montreal, Vol. 80, pp. 70 - 71, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, CANADA, Montreal, 17 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400096&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2019, 'Abstract 2884: Establishment of patient-derived xenograft models for high-risk neuroblastoma', in Cancer Research, American Association for Cancer Research (AACR), Vol. 79, pp. 2884 - 2884, http://dx.doi.org/10.1158/1538-7445.am2019-2884
, 2019, 'Abstract 2884: Establishment of patient-derived xenograft models for high-risk neuroblastoma', American Association for Cancer Research (AACR), pp. 2884 - 2884, presented at Tumor Biology, http://dx.doi.org/10.1158/1538-7445.sabcs18-2884
, 2019, 'Abstract 3659: Alyref is a novel binding partner and co-factor for MYCN-driven oncogenesis in neuroblastoma', in Cancer Research, American Association for Cancer Research (AACR), Vol. 79, pp. 3659 - 3659, http://dx.doi.org/10.1158/1538-7445.am2019-3659
, 2019, 'Abstract 4741: Re-evaluating the role of P-glycoprotein in the resistance of high-risk neuroblastoma to standard-of-care chemotherapies', American Association for Cancer Research (AACR), pp. 4741 - 4741, presented at Experimental and Molecular Therapeutics, http://dx.doi.org/10.1158/1538-7445.sabcs18-4741
, 2019, 'Abstract 4741: Re-evaluating the role of P-glycoprotein in the resistance of high-risk neuroblastoma to standard-of-care chemotherapies', in Cancer Research, American Association for Cancer Research (AACR), Vol. 79, pp. 4741 - 4741, http://dx.doi.org/10.1158/1538-7445.am2019-4741
, 2019, 'RESULTS OF THE ZERO CHILDHOOD CANCER INTEGRA-TM PRECISION MEDICINE PLATFORM FOR PAEDIATRIC HIGH-RISK BRAIN TUMOURS', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, CA, San Francisco, Vol. 21, pp. 118 - 118, presented at 5th Biennial Conference of the Society-for-Neuro-Oncology on Pediatric Neuro-Oncology Basic and Translational Research, CA, San Francisco, 03 May 2019 - 04 May 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000473243700229&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2019, 'Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Atlanta, GA, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Atlanta, GA, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-3111
, 2018, 'Zero Childhood Cancer: A Comprehensive Precision Medicine Platform for Children with High-Risk Cancer', in PEDIATRIC BLOOD & CANCER, WILEY, Vol. 65, pp. S643 - S644, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000445195005221&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2018, 'Abstract LB-137: Integrated genomics: drug screening and personalized xenograft development approach to identify precision treatments for aggressive pediatric brain tumors', in Cancer Research, American Association for Cancer Research (AACR), Vol. 78, pp. lb-137-lb-137, http://dx.doi.org/10.1158/1538-7445.am2018-lb-137
, 2018, 'Abstract LB-138: Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer', in Cancer Research, American Association for Cancer Research (AACR), Vol. 78, pp. lb-138-lb-138, http://dx.doi.org/10.1158/1538-7445.am2018-lb-138
, 2018, 'TARGETING THE POLYAMINE PATHWAY AS A NOVEL THERAPEUTIC TREATMENT AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, CO, Denver, Vol. 20, pp. 49 - 49, presented at 18th International Symposium on Pediatric Neuro-Oncology (ISPNO), CO, Denver, 30 June 2018 - 03 July 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000438339000097&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2018, 'DIPG-01. TARGETING THE POLYAMINE PATHWAY AS A NOVEL THERAPEUTIC TREATMENT AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', in Neuro-Oncology, Oxford University Press (OUP), Vol. 20, pp. i49 - i49, http://dx.doi.org/10.1093/neuonc/noy059.095
, 2018, 'PO-028 Effective targeting of NAD+biosynthesis in patient-derived xenograft models of high-risk paediatric acute lymphoblastic leukaemia', in ESMO Open, Elsevier, Vol. 3, pp. a238, http://dx.doi.org/10.1136/esmoopen-2018-eacr25.563
, 2017, 'REPOSITIONING EXISTING DRUGS AS NOVEL THERAPEUTICS: OXIDATIVE STRESS AS A TARGET FOR HIGH-RISK LEUKAEMIA IN CHILDREN', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, SPAIN, Madrid, Vol. 102, pp. 27 - 27, presented at 22nd Congress of the European-Hematology-Association, SPAIN, Madrid, 22 June 2017 - 25 June 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000404127001055&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2017, 'TRTH-05. PREDICTORS OF SUCCESS OF PHASE 2 PAEDIATRIC ONCOLOGY CLINICAL TRIALS', in Neuro-Oncology, Oxford University Press (OUP), Vol. 19, pp. iv52 - iv52, http://dx.doi.org/10.1093/neuonc/nox083.217
, 2017, 'Pilot study of a comprehensive precision medicine platform for children with high-risk cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 35, pp. 10539 - 10539, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.10539
, 2016, 'Comparison of MRD Levels and Gene Expression Patterns in MLL-R Versus Non-MLL Infant ALL', in Blood, American Society of Hematology, Vol. 128, pp. 1740, http://dx.doi.org/10.1182/blood.v128.22.1740.1740
, 2016, 'Abstract B23: Selective and rapid killing of mixed lineage leukemia and CALM-AF10 leukemia by SM7, a novel small molecule identified by chemical library screening', in Cancer Research, American Association for Cancer Research (AACR), Vol. 76, pp. b23 - b23, http://dx.doi.org/10.1158/1538-7445.pedca15-b23
, 2015, 'Improved Concordance of Minimal Residual Disease Measurements By Quantitative PCR and 10-Color Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia', in Blood, American Society of Hematology, Vol. 126, pp. 2614, http://dx.doi.org/10.1182/blood.v126.23.2614.2614
, 2015, 'Abstract 146: The long noncoding RNA MALAT1 promotes hypoxia-driven angiogenesis by upregulating pro-angiogenic gene expression in neuroblastoma cells', in Cancer Research, American Association for Cancer Research (AACR), Vol. 75, pp. 146 - 146, http://dx.doi.org/10.1158/1538-7445.am2015-146
, 2015, 'Abstract 1611: The FACT histone chaperone complex is highly expressed in aggressive drug refractory childhood cancers and the anti-FACT compound CBL0137 represents a highly promising therapeutic approach in this setting', in Cancer Research, American Association for Cancer Research (AACR), Vol. 75, pp. 1611 - 1611, http://dx.doi.org/10.1158/1538-7445.am2015-1611
, 2011, 'THE VALUE OF MONITORING FOR MRD AT LATE TIMEPOINTS IN PAEDIATRIC ALL TREATMENT', in PEDIATRIC BLOOD & CANCER, WILEY PERIODICALS, INC, Vol. 57, pp. 707 - 707, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000295239600003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2011, 'Abstract 3027: SIRT1 promotes N-Myc oncogenesis stabilizing N-Myc protein', in Cancer Research, American Association for Cancer Research (AACR), Vol. 71, pp. 3027 - 3027, http://dx.doi.org/10.1158/1538-7445.am2011-3027
, 2011, 'Abstract 5237: Development of organ-selective neuroblastoma cell lines to identify genes mediating bone marrow and liver colonization', in Cancer Research, American Association for Cancer Research (AACR), Vol. 71, pp. 5237 - 5237, http://dx.doi.org/10.1158/1538-7445.am2011-5237
, 2008, 'The value of monitoring for minimal residual disease post-transplant in children with acute lymphoblastic leukaemia', in British Journal of Haematology, Blackwell Publishing Ltd, Oxford, England, pp. 102 - 102, presented at Abstracts of the British Society of Haematology 48th Annual Scientific Meeting, incorporating the 6th Bi-Annual I-BFM Leukaemia Symposium
, 2006, '169 POSTER Sensitisation of neuroblastoma tumours to chemotherapy by use of a novel class of MRP1 small molecule inhibitor', in European Journal of Cancer Supplements, Elsevier, Vol. 4, pp. 54, http://dx.doi.org/10.1016/s1359-6349(06)70175-6
, 2006, '252A ORAL Relapse in children with acute lymphoblastic leukaemia is associated with selection of a pre-existing drug resistance subclone', in European Journal of Cancer Supplements, Elsevier, Vol. 4, pp. 81, http://dx.doi.org/10.1016/s1359-6349(06)70257-9
, 2004, 'Minimal residual disease in childhood acute lymphoblastic leukemia: A comparative study of flow cytometry and quantitative real-time polymerase chain reaction (RQ-PCR)', in BLOOD, AMER SOC HEMATOLOGY, CA, San Diego, Vol. 104, pp. 209B - 209B, presented at 46th Annual Meeting of the American-Society-of-Hematology, CA, San Diego, 04 December 2004 - 07 December 2004, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000225127700834&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2004, 'Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: A Comparative Study of Flow Cytometry and Quantitative Real-Time Polymerase Chain Reaction (RQ-PCR).', in Blood, American Society of Hematology, Vol. 104, pp. 4504, http://dx.doi.org/10.1182/blood.v104.11.4504.4504